Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir
HIV/AIDS
About this trial
This is an interventional treatment trial for HIV/AIDS focused on measuring Chidamide,CAR cell therapy,TCR cell therapy
Eligibility Criteria
Inclusion Criteria:
- HIV infection confirmed
- Receiving cART more than 12 months.
- HIV viral-load < 50 copies/ml and CD4 cell count more than 350 cells/ul.
- Without serious liver , heart, liver and kidney diseases.
- The subjects know about the study and volunteer to attend the research and sign the informed consent.
Exclusion Criteria:
- With active HBV or HCV infection, or serious opportunistic infections.
- With serious chronic disease such like diabetes, the mental illness,et al
- History of suffering from pancreatitis during cART .
- Pregnant or breast-fed.
- With poor adherence.
- Unable to complete follow up.
Sites / Locations
- Guangzhou 8th People's Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Chidamide combined with CAR-T or TCR-T cell therapy
without intervention
Receiving chidamide combined with CAR-T or TCR-T cell therapy based on based on cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections.
Not receiving chidamide combined with CAR-T or TCR-T cell therapy but continuing cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.